semaglutide soul study SOUL: Oral Bests Usual Care in High-Risk Type 2 Diabetes Forecasting Trial Milestones: A Predictive – Oral semaglutide (14 mg) demonstrates

Gastroparesis can cause severe nausea, vomiting, and other symptoms

nausea, vomiting, diarrhea), which tend to be mild and short-lived

FDA Restrictions on Compound GLP-1 Medications This regulatory action follows the FDA's February 2025 declaration that the semaglutide shortage is officially "resolved." For compounded tirzepatide (Zepbound), the deadline was earlier - March 2025

In both preclinical and clinical studies, semaglutide has demonstrated robust improvements in glycemic control together with significant reductions in body weight, largely through the modulation of central appetite pathways and reduced food intake [2,3]

Meanwhile, GLP-1 receptor agonists, such as semaglutide and liraglutide, enhance insulin secretion, suppress appetite, and slow gastric emptying, facilitating weight loss